E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Locally advanced or metastatic basal cell carcinoma (BCC) |
Carcinoma basocelular (CBC) localmente avanzado o metastásico |
|
E.1.1.1 | Medical condition in easily understood language |
Basal Cell Carcinoma |
Carcinoma basocelular |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10004146 |
E.1.2 | Term | Basal cell carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic BCC |
Evaluar la seguridad de vismodegib (GDC-0449) en pacientes con CBC localmente avanzado o metastásico |
|
E.2.2 | Secondary objectives of the trial |
- To assess the overall response (according to RECIST Version 1.1) in those patients with measurable disease as permitted by local regulatory requirement.
- To assess other efficacy parameters such as time to response, duration of response, progression-free survival and overall survival.
- To assess patient quality of life |
- Evaluar la respuesta global (conforme a RECIST Versión 1.1) en aquellos pacientes con enfermedad medible, si lo permiten los requisitos reguladores globales.
- Evaluar otros parámetros de eficacia, tales como el tiempo hasta la respuesta, la duración de la respuesta, la supervivencia libre de progresión y la supervivencia global.
- Evaluar la calidad de vida del paciente |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Adult patients, >/=18 years of age
- Metastatic or locally advanced basal cell carcinoma considered inoperable or that surgery is contraindicated and radiotherapy is contraindicated or inappropriate
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 |
- Pacientes adultos, edad ? 18 años.
- Pacientes con Carcinoma basocelular localmente avanzado o metastásico considerados inoperables o donde la cirugía esta contraindicada y la radioterapia esta contraindicada o no es apropiada.
- Estado funcional del Eastern Cooperative Oncology Group (ECOG) 0, 1 o 2. |
|
E.4 | Principal exclusion criteria |
- Concurrent anti-tumor therapy
- Completion of the most recent anti-tumor therapy less than 21 days prior to the initiation of treatment
- Uncontrolled medical illnes |
- Administración concomitante de tratamientos antitumorales
- Pacientes que hayan completado el tratamiento antitumoral más reciente menos de 21 días antes de iniciar el tratamiento del estudio.
- Enfermedades no controladas |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective of this trial is to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic BCC. |
El objetivo principal de este estudio es evaluar la seguridad de vismodegib (GDC-0449) en pacientes con CBC localmente avanzado o metastásico. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Until disease progression or unacceptable toxicity (approximately 2 years) |
Hasta progresión de la enfermedad o toxicidad inaceptable (aproximadamente 2 años) |
|
E.5.2 | Secondary end point(s) |
- Tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST)
- Time to response
- Duration of response
- Progression-free survival
- Overall survival |
- Índice de respuesta global (de acuerdo con los criterios RECIST, versión 1.1)
- Tiempo hasta la respuesta
- Duración de la respuesta
- Supervivencia libre de progresión
- Supervivencia global. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Until disease progression or unacceptable toxicity (approximately 2 years) |
Hasta progresión de la enfermedad o toxicidad inaceptable (aproximadamente 2 años) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 70 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Austria |
Bulgaria |
Canada |
France |
Germany |
Greece |
Hungary |
Italy |
Russian Federation |
Serbia |
Slovenia |
Sweden |
Turkey |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end when the last patient enrolled in this study develops progressive disease (as determined by the investigator), unacceptable toxicity, withdraws consent, dies, or the treating physician deems that patient is no longer benefitting from treatment or the study is terminated by the sponsor. |
Todos los pacientes recibirán el fármaco del estudio hasta que manifiesten progresión de la enfermedad (de acuerdo con la evaluación del investigador), toxicidad inaceptable, hasta que retiren su consentimiento, fallezcan, hasta que el médico responsable del tratamiento decida suspenderlo si lo considera necesario o hasta que el promotor cancele el estudio |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |